Jak leczymy i dokąd zmierzamy w terapii AMD?

• Authors: Anna Święch-Zubilewicz , Joanna Dolar-Szczasny , Jerzy Mackiewicz

Title variants

EN

How do we treat and where do we go in AMD treatment?

• Languages of publication: PL

Abstracts

PL

Zwyrodnienie plamki żółtej związane z wiekiem dotyczy coraz większej liczby chorych po 50. r.ż., jednakże etiologia tego schorzenia nie została dotychczas dokładnie poznana. Terapie stosowane w wysiękowej postaci AMD, takie jak radioterapia, laseroterapia czy fototerapia dynamiczna, okazały się nieskuteczne i obecnie standardem w leczeniu tego schorzenia jest podawanie doszklistkowe leków z grupy antagonistów VEGF, takich jak ranibizumab, aflibercept czy off-label bewacyzumab. Preparaty powyższe nie likwidują jednak przyczyny AMD, ale mają głównie działanie objawowe. Przypuszczalna wieloczynnikowa etiologia AMD wskazuje na konieczność poszukiwania nowych metod leczenia tego schorzenia. W związku z tym w fazie badań są leki wpływające na układ immunologiczny, substancje neuroprotekcyjne, antyoksydacyjne, terapie genowe

EN

The number of patients with age-related macular degeneration in population over 50 increases constantly, however the exact etiology of that pathology is still not well known. Previously used wet AMD treatment methods such as radiotherapy, laser therapy or photodynamic therapy were not successful. Now the gold standard for wet AMD treatment is the use of intravitreally administered anti-VEGF antagonists such as ranibizumab, aflibercept or off-label bevacizumab. However these medications are directed against the symptoms and not the cause of described pathology. Probable multifactorial etiology of AMD needs further improvement in therapy of that disease. New immunomodulators, neuroprotectors, antioxidants as well as gene therapy is currently under investigations to improve AMD treatment.

Keywords

EN

postać sucha; postać wysiękowa; terapia; zwyrodnienie plamki żółtej związane z wiekiem

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2014
• Volume: 1
• Issue: 1
• Pages: 4-10

Contributors

author

Anna Święch-Zubilewicz

• Klinika Chirurgii Siatkówki i Ciała Szklistego, Uniwersytet Medyczny w Lublinie

author

Joanna Dolar-Szczasny

• Klinika Chirurgii Siatkówki i Ciała Szklistego, Uniwersytet Medyczny w Lublinie

author

Jerzy Mackiewicz

• Klinika Chirurgii Siatkówki i Ciała Szklistego, Uniwersytet Medyczny w Lublinie

References

• 1. Aiello L.P., Northrup J.N., Keyt B.A. et al.: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalmol. 1995; 113(12): 1538-44.
• 2. Aird W.C.: Endothelial cell heterogeneity. Crit. Care Med. 2003; 31: 221-230.
• 3. Arnold J.J., Blinder K.J., Bressler N.M. et al.: Treatment of age-related macular degeneration with Photodynamic Therapy Study Group. Acute severe visual acuity decrease after photodynamic therapy with verterporfiryn: case report from randomized clinical trials-TAP and VIP report. Am. J. Ophthalmol. 2004; 137: 683-696.
• 4. Bressler N.M.: Early detection and treatment of neovascular age-related macular degeneration. J. Am. Board Pract. 2002; 15(2): 142-52.
• 5. Ciulla T.A., Danis R.P., Harris A.: Age-related macular degeneration: A review of experimental treatments. Surv. Ophthalmol. 1998; 43(2): 134-46.
• 6. Das A., Mc Guire P.G.: Retinal and choroidal angiogenesis: Pathophysiology and strategies for inhibition. Prog. Retin. Eye Res. 2003; 22(6): 721-48.
• 7. Ferrara N., Gerber H.P., LeCouter J.: The biology of vascular endothelial growth factor. Endocr. Rev. 2003; 18(1): 4-25.
• 8. Fine S.L., Berger J.W., Maguire M.G. et al.: Age-related macular degeneration and blindness due to neovascular maculopathy. N. Engl. J. Med. 2000; 342(7): 483-92.
• 9. Gilies M.C., Simpson J.M., Luo W. et al.: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration; one year results. Arch. Ophthalmol. 2003; 121: 667-673.
• 10. Grossniklaus H.E., Green W.R.: Choroidal neovascularisation. Am. J. Ophthalmol. 2004; 137: 496-503.
• 11. Hubschman J.P., Reddy S., Schwartz S.D.: Age-related macular degeneration: experimental and emerging treatments. Clin. Ophthalmol. 2009; 3: 167-174.
• 12. Hue J., Spee C., Kase S. et al.: Recombinant human VEGF 165 b inhibits experimental choroidal neovascularisation. IOVS 2010; 51(8): 4282-8.
• 13. Jager R.D., Aiello L.P., Patel C.S. et al.: Risks of intravitreus injection: a comprehensive review. Retina 2004; 24: 676-698.
• 14. Liu M., Regillo C.D.: A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials. Curr. Opin. Ophthalmol. 2004; 15: 221-226.
• 15. Papadopoulos N., Martin J., Ruan Q. et al.: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012: 15(2): 171-185.
• 16. Patel S.: Combination therapy for age-related macular degeneration. Retina 2009; 29(6): 45-8.
• 17. Schmidt-Erfurth U., Kaiser P.K., Korobelnik J.F.: Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014; 121(1): 193-201.
• 18. Serini S., Piccioni E., Calviello G.: Dietary n-3 PUFA vascular targeting and the prevention of tumor growth and age-related macular degeneration. Curr. Med. Chem. 2009; 16(34): 4511-26.
• 19. Weber B.H., Charbel Issa P., Pauly D. et al.: The role of the complement system in age-related macular degeneration. Dtsch Arztebl. Int. 2014; 11(8): 133-8.

• Document Type: article